Biotech Values

[poorgradstudent]

QURE:

Sort of plays off the monogenic comment you had made on Twitter and which I had been thinking about in regards to preclinical models of HF.

I think QURE is doing everything right so far. I've been looking at their preclinical data and comparing it to other similar models that have progressed to (and failed in) the clinic with the hope of finding a differentiator or observation that can set them apart. Not really seeing one.

This is no different a quandary than all the preclinical cancer models that are successful yet flop in the clinic. Hopefully I'll live long enough to see what the underlying mechanism is that blocks the successful translation of many treatments.